Tirzepatide may not increase risk for diabetic retinopathy in type 1 diabetes

Satish K. Garg, MD, professor of medicine and pediatrics at the Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, said there has been interest in assessing the impact incretin-based medications have on eye disease ever since the SUSTAIN-6 trial found semaglutide (Ozempic, Novo Nordisk) was associated with increased risk for diabetic retinopathy.